CAR-T cell therapy: CAR T-cell therapy uses genetically engineered T cells to intensify the immune systems response to cancer. T-cells with chimeric antigen receptor recognize and kill the cancer cells in the body.
Photo Source: iStock/Getty Images Plus
In a monumental stride forward in the fight against cancer, immunotherapy has emerged as a paradigm shift, offering new hope for patients worldwide. This groundbreaking approach harnesses the body’s own immune system to recognize and combat cancer cells, marking a departure from conventional treatments like chemotherapy and radiation therapy. Cancer immunology, once relegated to the periphery of oncological research, has now assumed center stage in the fight against cancer.
Recent advancements in cancer treatment have brought immunotherapy to the forefront, showcasing notable breakthroughs in several key areas. A significant stride in this domain is the development of immune checkpoint inhibitors, exemplified by drugs like ipilimumab, pembrolizumab, and nivolumab. This groundbreaking class of cancer immunotherapy has revolutionized oncology by leveraging the body’s immune system to combat cancer. Scientists like James P. Allison and Tasuku Honjo played pivotal roles in discovering these inhibitors, which target regulatory checkpoints such as CTLA-4 and PD-1/PD-L1. By blocking these inhibitory pathways, immune checkpoint inhibitors unleash the immune system’s potential to identify and eliminate cancer cells more effectively, leading to transformative improvements in treatment outcomes for patients with various malignancies.
The development of adoptive cell therapy, including CAR-T cell therapy, offers a personalized approach to cancer treatment by utilizing the patient’s own immune cells to target and eliminate tumors. CAR-T cell therapy, a groundbreaking form of immunotherapy, involves genetically modifying a patient’s T cells to enhance their ability to recognize and attack cancer cells. This approach has demonstrated remarkable success in treating certain blood cancers, particularly in patients unresponsive to conventional treatments. CAR-T cell therapy involves collecting T cells from a patient, genetically modifying them in a lab to express chimeric antigen receptors (CARs), expanding their numbers, conditioning the patient’s immune system, infusing the modified cells back into the patient, where they become activated upon encountering cancer cells, leading to their destruction. Patients are closely monitored for side effects and efficacy, requiring follow-up treatments or supportive care as needed.
Although significant progress has been made, obstacles remain, such as the emergence of resistance mechanisms and the considerable expense associated with treatment. Scientists are actively investigating methods to counter resistance, including combining therapies and identifying new immune targets. Additionally, initiatives are in progress to enhance accessibility and affordability, aiming to guarantee fair access to these vital treatments for all patients requiring them.
The journey of cancer immunology from a fringe idea to a game-changer in cancer treatment epitomizes the power of scientific discovery and innovation. As we continue to unravel the complexities of the immune-tumor interaction, immunotherapy holds tremendous promise for transforming the landscape of cancer care. By building on past successes and addressing current challenges, we can harness the full potential of the immune system to combat cancer and improve patient outcomes.
– Dr. Sudeep Adhikari (MD)
Consultant
BPKMCH, Chitwan
